`PATENT AND TRADEMARK OFFICE
`
`Page 1 of 2
`sloxanaie, veAse 88
`
`Alexandita,
`VA
`22213
`
`
`ELECTRONIC ACKNOWLEDGEMENT RECEIPT
`
`APPLICATION #
`17/352,892
`
`RECEIPT DATE / TIME
`02/28/2023 02:40:33 PM ET
`
`ATTORNEY DOCKET#
`REGN-008CIPCON10
`
`Title of Invention
`
`USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
`
`Application Information
`
`APPLICATION TYPE_Utility - Nonprovisional Application PATENT # 11253572
`
`
`under 35 USC 11 1(a)
`
`
`
`CONFIRMATION #
`
`5070
`
`FILED BY Kathi Moore
`
`PATENT CENTER#
`
`61663248
`
`FILING DATE
`
`06/21/2021
`
`CUSTOMER #
`
`96387
`
`CORRESPONDENCE
`
`-
`
`Documents
`
`FIRST NAMED George YANCOPOULOS
`INVENTOR
`
`AUTHORIZED BY Michael Lewis
`
`TOTAL DOCUMENTS: 2
`
`DOCUMENT
`
`PAGES
`
`DESCRIPTION
`
`SiZk (KB)
`
`PSSO056US 13-37Sc. padi
`
`POA-Regeneron. pal
`
`Digest
`
`3
`
`&
`
`Assignee showing of ownership
`per 37 GER 3.73
`
`TTO KB
`
`Power of Attorney
`
`S8TO KE
`
`DOCUMENT
`
`MESSAGE DRAEST(SNA-512)}
`
`PSSOS8USTS-373c. pedi
`
`SSS 1S6C7SRRS 1 OSF2FS 1 19e45C7CerAABBFRE4AAC 1 GORFS756
`A&S2FFOEFZOG21 3F8 1874848000734321 BB I AE SBCFOBSESET
`
`BS PD0GE 7S40R 7 F4047 TE PFCQGA7695
`
`
`
`POA-Regeneran. pd
`
`SDECEOSD2FS1 BBCDBS7EGPAE496644 EG BGAGD74B0C0A1 4B4
`FESIGDSOTSETECSS83171 O07BRADAGE 1 O76CAS95ADB4CH61 BA
`
`9ESC 1TSDA4T SBCO4ASCEFF 1OB? 1 SAQG75
`
`Page 2 of 2
`
`
`
`& USRTCO of the indicated documents, characierize
`a Acknowledgement eeavidances raceint an f & noted date by
`weserbed.ma MPEP 503.
`
`ne apohcant,
`
`ar
`
`ag page counts, where applic
`
`iot sinller io a Post Carel, as
`
`New Applications Under 35 US.G. itt
`
`7.580b}-io)
`Ha new application is being fied and the aonlicalion inciucies the necessary companenis forTeg dale (gee 37{
`
`
`and MPEP 506), a Filing ReceiptHS7 OFR 1.54) will be issued in due course and the dafe shownon this Ac“krowledgement
`
`
`Receiot wil astabtish the fling date of the anniicaiion
`
`National Stage of an international Application uncer 35 U.S.C. 374
`
`a timely submission to enter the national stage of an internalonal apolicadion is campllant wih the concdifions of S35 U.S.o.
`ve and other anplicable requiramenis a Form PCT/DO/EO/909
`indicating acceptance af the application as a national stage
`omission uncer 35 UlS.0. 377 will be issued in acelition to the Fing Receipt, im due course,
`
`New Infernational Apolisation Filed with the USPTO as a Recelving Office
`
`H a rawinternational application is being HHecl and ihe internalional aomlication includes _ necessary components for an
`international fing cate (see PCTAnes Tiant MPEP 1810), a Notification of the International Appheation Number and af the
`international Filing Date (Form PCT/RO/105) will be issued in due course, subject lo preacrintians concerning national securly,
`ancthe cate shown on this Acknowiedgement Neceict will establish
`ine interdational fina daie of the applicaiion.
`
`